LEADER-PAD
The Low dose ColchicinE in pAtients with peripheral Artery DiseasE to address residual vascular Risk (LEADER-PAD) trial will evaluate if anti-inflammatory therapy with colchicine will reduce vascular events in patients with symptomatic peripheral…
- Investigator
- Samir K Shah
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
STRIDE II
- Investigator
- Benjamin N Jacobs
- Status
- Accepting Candidates
PERMET
The PERMET trial will determine whether metformin daily for six months improves six-minute walk performance in individuals with peripheral artery disease compared to placebo.
- Investigator
- Scott A Berceli
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All